roxadustat - dofaq.co
網球》前球后哈勒普控營養品廠商 含禁藥及不明中國成分
自由時報 - 21 Feb 2024
網球》前球后哈勒普控營養品廠商 含禁藥及不明中國成分 ...
Simona Halep對禁藥案上訴理由是營養補充劑受污染
TSNA體育新聞團隊 - 29 Oct 2023
Simona Halep對禁藥案上訴理由是營養補充劑受污染 ...
A nomogram for predicting the risk of treatment failure of roxadustat in peritoneal dialysis with renal anemia | Scientific ...
Nature - 01 Apr 2024
A nomogram for predicting the risk of treatment failure of roxadustat in peritoneal dialysis with renal anemia | Scientific ... ...
《Nature》AZ、Fibrogen候選新藥roxadustat 成逆轉鐮刀型血球症新希望?!
環球生技月刊 - 19 Oct 2022
《Nature》AZ、Fibrogen候選新藥roxadustat 成逆轉鐮刀型血球症新希望?! ...
FDA declines to approve FibroGen's roxadustat for anaemia of CKD
Pharmaceutical Technology - 29 Nov 2022
FDA declines to approve FibroGen's roxadustat for anaemia of CKD ...
AstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure
Fierce Pharma - 27 Feb 2024
AstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure ...
FibroGen scores Phase III win in China for roxadustat
Clinical Trials Arena - 18 May 2023
FibroGen scores Phase III win in China for roxadustat ...
Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
ScienceDirect.com - 17 Apr 2021
Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD ...
Roxadustat a new option for CKD-related anaemia | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
MIMS - 27 Jun 2020
Roxadustat a new option for CKD-related anaemia | Latest news for Doctors, Nurses and Pharmacists | Pharmacy ...
AstraZeneca Returns to FibroGen the Rights to Roxadustat in US, Other Territories
BioSpace - 28 Feb 2024
AstraZeneca Returns to FibroGen the Rights to Roxadustat in US, Other Territories ...
Roxadustat Linked to Improved Iron Metabolism vs ESAs in Peritoneal Dialysis
HCPLive - 28 Nov 2023
Roxadustat Linked to Improved Iron Metabolism vs ESAs in Peritoneal Dialysis ...
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk ...
Yahoo Finance - 09 Dec 2023
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk ... ...
HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by ...
Nature - 08 Oct 2022
HIF-α activation by the prolyl hydroxylase inhibitor roxadustat suppresses chemoresistant glioblastoma growth by ... ...
打破拒批魔咒!FDA批GSK首款口服腎病貧血藥限「洗腎者用」
環球生技月刊 - 02 Feb 2023
打破拒批魔咒!FDA批GSK首款口服腎病貧血藥限「洗腎者用」 ...
FibroGen's AZ deal in danger after anemia drug fails in 2nd act
Fierce Pharma - 05 May 2023
FibroGen's AZ deal in danger after anemia drug fails in 2nd act ...
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis ...
Nature - 18 Sep 2023
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis ... ...
AstraZeneca, FibroGen's roxadustat hit with tough safety questions in FDA review ahead of key expert meeting
Fierce Pharma - 13 Jul 2021
AstraZeneca, FibroGen's roxadustat hit with tough safety questions in FDA review ahead of key expert meeting ...
Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients ...
Nature - 23 Feb 2023
Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients ... ...
AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meeting
Fierce Pharma - 10 Nov 2021
AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meeting ...